A new paper is out!
DIVERSA has participated in the development of innovative treatment for osteoarthritis in a project led by research groups from the Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS) at The University of Santiago de Compostela, and the Health Research Institutes of Santiago de Compostela (IDIS) and A Coruña (INIBIC).
Why is this treatment groundbreaking?
Injection of senotherapeutics is an innovative strategy to treat rheumatoid arthritis. However, when injected, their effectivity is restricted due to the rapid replacement of the synovial fluid and their low stability in biological fluids, which limits molecules’ half-life.
Encapsulation of a senolytic peptide into lipid-based nanoemulsions has allowed the therapeutic molecule to remain longer at the joint. This has been proved by PET imaging. The molecule has been radiolabeled with 89Zr before its incorporation into the lipid-based nanoemulsion, allowing tracking after intra-articular injection.
How does it work?
To participate in this program, your company must meet the following requirements:
The proposed system can simultaneously be used for diagnosis and treatment, i.e., as a theranostic. Radiolabeling allows for expanding the application for the selection of patients that can benefit from the proposed therapy, as well as for monitoring the kinetics and, eventually, the efficacy of the treatment.
The formulation has been tested in rats, where the encapsulated peptide had a higher retention time on the target site after administration than the free peptide. The following steps involve larger preclinical trials for testing safety, effectiveness, and therapeutic response.
We are delighted that our technology helps to bridge the gap from benchtop to bedside!
DIVERSA has currently opened positions for formulation scientists. Click here to join us!